Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Immucell Corp

NASDAQ: ICCC · Life Sciences · 3 alerts · CIK 811641

Share price
$11.42Close, Nov 16
Market cap
$104M
Shares outstanding
9.09MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immucell Corp filings on SEC EDGAR ↗

6:02 AM ET 8-K
Financial Results

Immucell Financial Results

ImmuCell reported Q3 2026 financial results with revenue growing 46% to $8.0 million and net income of $953,000. The company highlighted broad-based growth across sales territories and announced the termination of its At-The-Market (ATM) offering program due to a strong cash position.

Term
Q3 2026

“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions. Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”

Olivier te Boekhorst, President and CEO

“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025. Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025.”

Timothy C. Fiori, Chief Financial Officer
4:21 PM ET 10-Q
Financial Results

Immucell Q3 2026 Results: Turns Profitable, Net Income $953K

ImmuCell Corporation reported a settlement of $2.0 million with a former contract manufacturer and a $0.1 million regulatory fee reversal following the decision to cease focus on Re-Tain®. The company is currently refitting approximately $11.8 million in idle manufacturing assets for First Defense® production and reported anti-dilutive stock options totaling 968,978 for the quarter ended September 30, 2026.

Key figure
Net income $953K
6:03 AM ET 8-K
Business Update

Immucell Business Update

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2026, reporting total sales of $8.0 million, a 46% increase over the same period in 2025. The growth was driven by strong performance across its product portfolio, including a 51% increase in Tri-Shield sales and a 27.8% increase in total sales for the first nine months of the year.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.